To assess the efficacy and safety of a 24-week course of abatacept in the treatment of active lupus nephritis and to assess the potential of abatacept to induce `` clinical tolerance , '' defined as sustained clinical quiescence of lupus nephritis after discontinuation of immunosuppressive therapy .